MAPK3 and breast cancer: An in vitro study displayed that treating breast cancer cells with PEITC abrogated MAPK/ERK1/2 signaling pathway and down-regulated estrogen receptor (ER-α36), leading to the growth inhibition of breast cancer cells [102].